|
1. Spry CJ: The pathogenesis of endomyocardial fibrosis: the role of the eosinophil. In: Springer seminars in immunopathology: 1989. Springer: 471-477. 2. Broide DH, Gleich GJ, Cuomo AJ, Coburn DA, Federman EC, Schwarte LB, Wasserman SI: Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. Journal of Allergy and Clinical Immunology 1991, 88(4):637-648. 3. Trivedi S, Lloyd C: Eosinophils in the pathogenesis of allergic airways disease. Cellular and molecular life sciences 2007, 64(10):1269-1289. 4. OLSSON I, VENGE P: Cationic Proteins of Human Granulocytes: I. Isolation of the Cationic Proteins from the Granules of Leukaemic Myeloid Cells. Scandinavian journal of haematology 1972, 9(1‐6):204-214. 5. Olsson I, Venge P: Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells. Blood 1974, 44(2):235-246. 6. Olsson I, Venge P, Spitznagel J, Lehrer R: Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Laboratory investigation; a journal of technical methods and pathology 1977, 36(5):493-500. 7. Fredens K, Dybdahl H, Dahl R, Baandrup U: Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. Apmis 1988, 96(7‐12):711-719. 8. Silberstein DS: Eosinophil function in health and disease. Critical reviews in oncology/hematology 1995, 19(1):47-77. 9. Guilpain P, Guillevin L, Mouthon L: [Eosinophil granule cationic proteins: eosinophil activation markers]. La Revue de medecine interne/fondee par la Societe nationale francaise de medecine interne 2006, 27(5):406-408. 10. Niccoli G, Ferrante G, Cosentino N, Conte M, Belloni F, Marino M, Bacà M, Montone RA, Sabato V, Schiavino D: Eosinophil cationic protein: A new biomarker of coronary atherosclerosis. Atherosclerosis 2010, 211(2):606-611. 11. Khakzad MR, Mirsadraee M, Sankian M, Varasteh A, Meshkat M: Is serum or sputum eosinophil cationic protein level adequate for diagnosis of mild asthma? Iranian Journal of Allergy, Asthma and Immunology 2009, 8(3):155-160. 12. Koh GC-H, Shek LP-C, Goh DY-T, Van Bever H, Koh DS-Q: Eosinophil cationic protein: is it useful in asthma? A systematic review. Respiratory medicine 2007, 101(4):696-705. 13. Gleich GJ: Mechanisms of eosinophil-associated inflammation. Journal of Allergy and Clinical Immunology 2000, 105(4):651-663. 14. Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L, Adam E, Woerly G, Dombrowicz D, Capron M: TLR2-dependent eosinophil interactions with mycobacteria: role of α-defensins. Blood 2009, 113(14):3235-3244. 15. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann K, Gleich G: Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. The Journal of Immunology 1989, 142(12):4428-4434. 16. Torrent M, de la Torre B, Nogues V, Andreu D, Boix E: Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem J 2009, 421:425-434. 17. Hamann K, Gleich G, Checkel J, Loegering D, McCall J, Barker R: In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. The Journal of Immunology 1990, 144(8):3166-3173. 18. Badar A, Saeed W, Hussain MM, Aslam M: Correlation of eosinophil cationic protein with severity of asthma. Age (years) 2004, 34(12.17):36.27-39.78. 19. Choi J, Callaway Z, Kim HB, Fujisawa T, Kim CK: The role of TNF‐α in eosinophilic inflammation associated with RSV bronchiolitis. Pediatric Allergy and Immunology 2010, 21(3):474-479. 20. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF: Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic acids research 1998, 26(14):3358-3363. 21. Maeda T, Kitazoe M, Tada H, de Llorens R, Salomon DS, Ueda M, Yamada H, Seno M: Growth inhibition of mammalian cells by eosinophil cationic protein. European Journal of Biochemistry 2002, 269(1):307-316. 22. Motojima S, Frigas E, Loegering DA, Gleich GJ: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. American Review of Respiratory Disease 1989, 139(3):801-805. 23. Carreras E, Boix E, Navarro S, Rosenberg HF, Cuchillo CM, Nogués MV: Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. Molecular and cellular biochemistry 2005, 272(1-2):1-7. 24. Goto T, Morioka J, Inamura H, Yano M, Kodaira K, Igarashi Y, Abe S, Kurosawa M: Urinary eosinophil-derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity. Allergology International 2007, 56(4):433-438. 25. Durack DT, Ackerman SJ, Loegering DA, Gleich GJ: Purification of human eosinophil-derived neurotoxin. Proceedings of the National Academy of Sciences 1981, 78(8):5165-5169. 26. Rosenberg HF, Tenen DG, Ackerman SJ: Molecular cloning of the human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. Proceedings of the National Academy of Sciences 1989, 86(12):4460-4464. 27. Rosenberg HF, Dyer KD: Eosinophil cationic protein and eosinophil-derived neurotoxin Evolution of novel function in a primate ribonuclease gene family. Journal of Biological Chemistry 1995, 270(37):21539-21544. 28. Slifman N, Loegering D, McKean D, Gleich G: Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. The Journal of Immunology 1986, 137(9):2913-2917. 29. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U: Roles of heparan-sulphate glycosaminoglycans in cancer. Nature Reviews Cancer 2002, 2(7):521-528. 30. Barker RL, Loegering DA, Ten RM, Hamann KJ, Pease L, Gleich G: Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases. The Journal of Immunology 1989, 143(3):952-955. 31. Larkin MA, Blackshields G, Brown N, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R: Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23(21):2947-2948. 32. Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446(7139):1030-1037. 33. Munoz EM, Linhardt RJ: Heparin-binding domains in vascular biology. Arteriosclerosis, thrombosis, and vascular biology 2004, 24(9):1549-1557. 34. Capila I, Linhardt RJ: Heparin–protein interactions. Angewandte Chemie International Edition 2002, 41(3):390-412. 35. Hung T-J, Tomiya N, Chang T-H, Cheng W-C, Kuo P-H, Ng S-K, Lien P-C, Lee Y-C, Chang MD-T: Functional characterization of ECP-heparin interaction: A novel molecular model. 2013. 36. Fan T-c, Fang S-l, Hwang C-s, Hsu C-y, Lu X-a, Hung S-c, Lin S-C, Chang MD-T: Characterization of molecular interactions between eosinophil cationic protein and heparin. Journal of Biological Chemistry 2008, 283(37):25468-25474. 37. García-Mayoral MF, Moussaoui M, Beatriz G, Andreu D, Boix E, Nogués MV, Rico M, Laurents DV, Bruix M: NMR structural determinants of eosinophil cationic protein binding to membrane and heparin mimetics. Biophysical journal 2010, 98(11):2702-2711. 38. García-Mayoral MF, Canales An, Díaz D, López-Prados J, Moussaoui M, de Paz JL, Angulo Js, Nieto PM, Jiménez-Barbero Js, Boix E: Insights into the glycosaminoglycan-mediated cytotoxic mechanism of eosinophil cationic protein revealed by NMR. ACS chemical biology 2012, 8(1):144-151. 39. Sl F, Tc F, Fu H, Chen C, Hwang C, Antopolsky M: A novel cell-penetrating peptide derived from human eosinophil cationic protein. PloS one 2013, 8(3):e57318. 40. 陳勝智, 連金城: 為碳序法之化學結構產生法尋求資料豐富的核磁共振光譜? 2004. 41. Jelinski LW: Modern NMR Spectroscopy. Chemical and Engineering News 1984, 62(45). 42. Otting G: NMR studies of water bound to biological molecules. Progress in Nuclear Magnetic Resonance Spectroscopy 1997, 31(2):259-285. 43. Spera S, Bax A: Empirical correlation between protein backbone conformation and C. alpha. and C. beta. 13C nuclear magnetic resonance chemical shifts. Journal of the American Chemical Society 1991, 113(14):5490-5492. 44. Schwarzinger S, Kroon GJ, Foss TR, Chung J, Wright PE, Dyson HJ: Sequence-dependent correction of random coil NMR chemical shifts. Journal of the American Chemical Society 2001, 123(13):2970-2978. 45. Morris KF, Johnson Jr CS: Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy. Journal of the American Chemical Society 1992, 114(8):3139-3141. 46. Johnson Jr C: Prog. NMR Spectrosc. 1999, 34, 203.[CrossRef],[CAS] Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications Johnson, CS, Jr. Progress in Nuclear Magnetic Resonance Spectroscopy 1999, 34(3):4. 47. 陳一帆: 以磁場梯度核磁共振技術測定幾丁聚醣分子量. 2006. 48. Lakowicz JR: Principles of Fluorescence Spectroscopy. 49. Teale F: The ultraviolet fluorescence of proteins in neutral solution. Biochemical Journal 1960, 76(2):381. 50. Komath SS, Swamy MJ: Fluorescence quenching, time-resolved fluorescence and chemical modification studies on the tryptophan residues of snake gourd (Trichosanthes anguina) seed lectin. Journal of Photochemistry and Photobiology B: Biology 1999, 50(2):108-118. 51. Hennessey Jr JP, Johnson Jr WC: Information content in the circular dichroism of proteins. Biochemistry 1981, 20(5):1085-1094. 52. 李黠汝: 肝癌衍生生長因子 PWWP 區域第一個胺基酸對蛋白質穩定性與受體結合能力的影響. 清華大學生物資訊與結構生物研究所學位論文 2013:1-63. 53. Torrent M, Cuyás E, Carreras E, Navarro S, López O, de la Maza A, Nogués MV, Reshetnyak YK, Boix E: Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 2007, 46(3):720-733. 54. 杜慶璋: 體制素分子內氫鍵之研究. 2002.
|